The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

##STR00001##

The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula I-I all have the meaning as defined herein.

##STR00001##

The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula I-I all have the meaning as defined herein.

##STR00001##

Disclosed is a compound of formula (I) in which R.sup.1-R.sup.5 and X.sup.1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.

##STR00001##

Disclosed is a compound of formula (I) in which R.sup.1-R.sup.5 and X.sup.1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.

##STR00001##

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula all have the meaning as defined herein.

##STR00001##

The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R.sup.1, R.sup.2, R.sup.3, X.sup.1, X.sup.2, A and Cy variable in Formula all have the meaning as defined herein.

##STR00001##

Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing, treating, and/or protecting against sensory hair cell death. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.

Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing, treating, and/or protecting against sensory hair cell death. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.

Disclosed are polycationic polymers. The polycationic polymers can include a plurality of positively charged centers, each of which is formed by condensation of cyclic bis-electrophile (e.g., a 9-thia/aza/selenabicyclo[3.3.1]nonyl electrophile) with a nucleophile. The resulting polycationic polymers can efficiently bind nucleic acids. The polycations can also exhibit properties of cytotoxicity and DNA transfection with interesting structure-activity characteristics.